Both the GLP-1R/GIP coagonist and the tri-agonist similarly reduced blood glucose levels and improved glucose tolerance without induction of hypoglycaemia, and this demonstrates that chronic GCGR agonism does not overpower the anti-hyperglycemic effects of GLP-1R and GIPR activation
Diabetes Care 19 , 580586 (1996)
Yes, but only as a treatment for type 2 diabetes, not for weight loss
Some patients find abdominal injections easiest because they can self-inject while standing in front of a mirror
Recent studies show that up to 60% of individuals seeking weight loss treatment report engaging in emotional eating behaviors
If your healthcare team determines a medication hold is appropriate, the duration should be individualized based on your specific medication, dosing frequency, and clinical factors